Investors

/Investors
Investors 2018-08-12T12:00:43+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

4.92
-0.09 (-1.70%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :4,764
Date :08-15-2018

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Granted Japanese Patent for GLP-1 Analog Capsule

July 24th, 2018|Comments Off on Oramed Granted Japanese Patent for GLP-1 Analog Capsule

NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property [...]

Oramed Announces Closing of $18.1 Million Registered Direct Offering

July 6th, 2018|Comments Off on Oramed Announces Closing of $18.1 Million Registered Direct Offering

NEW YORK, July 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the closing of its previously-announced registered direct [...]

Oramed Announces $18.1 Million Registered Direct Offering

July 3rd, 2018|Comments Off on Oramed Announces $18.1 Million Registered Direct Offering

NEW YORK, July 3, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive [...]

Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin

June 25th, 2018|Comments Off on Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin

Study will provide additional metabolic data on ORMD-0801 in patients with type 1 diabetes NEW YORK, June 25, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on [...]